Governors, Lawmakers Pressure FDA To Ease Market Entry Of Generic Insulin

Some federal lawmakers and governors have been lobbying FDA to ease the way for the production and sale of generic insulin, which analysts say would reduce the cost of diabetes treatment by 25%, the New York Times reports. Generic insulin could mean spending reductions for Medicaid programs -- which spent $500 million on the treatment in 2005 -- as well as for people with diabetes. In addition, some observers say that the availability of generic insulin could ease development of other drugs in the class of biologics, which are medicines made from living organisms. However, many scientists say duplication of such drugs could be difficult, as they are variable and could cause allergic reactions in patients.

Link to article in Medical News Today

Link to New York Times Article  

Additional information